We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Artivion (AORT - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Artivion is a member of the Medical sector. This group includes 947 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Artivion is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AORT's full-year earnings has moved 11.1% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that AORT has returned about 63.8% since the start of the calendar year. In comparison, Medical companies have returned an average of 8.7%. This means that Artivion is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Pacific Biosciences of California (PACB - Free Report) . The stock has returned 43.7% year-to-date.
Over the past three months, Pacific Biosciences of California's consensus EPS estimate for the current year has increased 9.2%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Artivion belongs to the Medical - Instruments industry, which includes 81 individual stocks and currently sits at #80 in the Zacks Industry Rank. Stocks in this group have gained about 6.7% so far this year, so AORT is performing better this group in terms of year-to-date returns. Pacific Biosciences of California is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Artivion and Pacific Biosciences of California as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Artivion (AORT - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Artivion is a member of the Medical sector. This group includes 947 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Artivion is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AORT's full-year earnings has moved 11.1% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that AORT has returned about 63.8% since the start of the calendar year. In comparison, Medical companies have returned an average of 8.7%. This means that Artivion is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Pacific Biosciences of California (PACB - Free Report) . The stock has returned 43.7% year-to-date.
Over the past three months, Pacific Biosciences of California's consensus EPS estimate for the current year has increased 9.2%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Artivion belongs to the Medical - Instruments industry, which includes 81 individual stocks and currently sits at #80 in the Zacks Industry Rank. Stocks in this group have gained about 6.7% so far this year, so AORT is performing better this group in terms of year-to-date returns. Pacific Biosciences of California is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Artivion and Pacific Biosciences of California as they could maintain their solid performance.